List of Excipients in Branded Drug EPLERENONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	EPLERENONE	eplerenone	59762-1107	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	EPLERENONE	eplerenone	59762-1107	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	EPLERENONE	eplerenone	59762-1107	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	EPLERENONE	eplerenone	59762-1107	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	EPLERENONE	eplerenone	59762-1107	HYPROMELLOSE
Mylan Pharmaceuticals Inc	EPLERENONE	eplerenone	59762-1107	LACTOSE

Generic Drugs Containing EPLERENONE

Company	Ingredient	NDC	Excipient
Eon Labs Inc	eplerenone	0185-5368	CELLULOSE, MICROCRYSTALLINE
Eon Labs Inc	eplerenone	0185-5368	CROSCARMELLOSE SODIUM
Eon Labs Inc	eplerenone	0185-5368	HYPROMELLOSE
Eon Labs Inc	eplerenone	0185-5368	LACTOSE MONOHYDRATE
Eon Labs Inc	eplerenone	0185-5368	MAGNESIUM STEARATE
Eon Labs Inc	eplerenone	0185-5368	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in EPLERENONE?

# Of NDCs	Excipient
16	CELLULOSE, MICROCRYSTALLINE
19	CROSCARMELLOSE SODIUM
2	D&C YELLOW NO. 10
4	FD&C BLUE NO. 2--ALUMINUM LAKE
1	FD&C YELLOW NO. 5
3	FD&C YELLOW NO. 6

Excipient Strategy and Commercial Opportunities for Eplerenone

Last updated: February 25, 2026

What is Eplerenone’s Excipient Strategy?

Eplerenone, marketed as Inspra by Pfizer, is a selective mineralocorticoid receptor antagonist approved for treating hypertension and heart failure. The formulation typically involves excipients that ensure stability, bioavailability, and patient compliance. Common excipients include:

• Microcrystalline cellulose for tablet binding.
• Sodium starch glycolate as a disintegrant.
• Magnesium stearate as a lubricant.
• Preservatives such as sodium benzoate in liquid forms.
• Coating agents like hypromellose for controlled release.

The excipient profile aligns with standard practices for oral solid dose forms, emphasizing compatibility and minimal drug-excipient interaction. Pfizer’s formulations focus on stability and ease of manufacturing.

What Are the Key Considerations in Eplerenone Excipient Selection?

Stability and Compatibility

Eplerenone's chemical stability influences excipient choice. Excipients must not react with the drug or promote degradation. For instance, excipients sensitive to moisture or pH may compromise shelf life.

Bioavailability Enhancement

Ingredients such as disintegrants improve dissolution. Eplerenone has moderate solubility; formulation strategies aim to optimize absorption through excipient selection that promotes disintegration and solubilization.

Patient Compliance

Taste masking and capsule/dosage form design rely on excipients that improve palatability and swallowing. The palatability of liquids may incorporate sweeteners like sucrose or sorbitol.

Manufacturing Considerations

Excipients must be readily available, cost-effective, and compatible with high-speed production processes. The use of common excipients reduces development times and risks.

What Are the Commercial Opportunities Linked to Eplerenone’s Excipient Strategy?

Patent Protection and Formulation Exclusivity

Pfizer holds patents on specific formulations. Developing novel excipient combinations or controlled-release formulations offers patentability, extending market exclusivity.

Improving Formulation Stability and Patient Compliance

Formulation enhancements can enable new delivery forms, such as once-daily controlled-release tablets or liquid suspensions, expanding patient segments and markets.

Cost Reduction Strategies

Utilizing cost-effective excipients can improve gross margins. Batch yield improvements and scalable excipient sourcing can also reduce unit costs.

Entry into Emerging Markets

Localized formulations with excipients tailored to regional preferences or regulatory requirements can facilitate market entry in regions with different excipient approvals.

Development of Specialized Formulations

Formulating for specific populations (e.g., pediatric, elderly) with excipients suited for these groups can open niche markets.

Regulatory Pathways and Approvals

Excipients with established safety profiles streamline approvals. Novel excipients require additional testing, but successful validation opens opportunities for transdermal or implantable versions.

Co-Formulation Opportunities

Combining eplerenone with other cardiovascular drugs in fixed-dose combinations calls for excipients compatible across multiple active ingredients, broadening commercial potential.

Competitive Landscape and Innovation Trends

Drug developers explore:

• Controlled-release systems with specific excipient matrices to extend dosing intervals.
• Liposomal or nanoparticle formulations for targeted delivery.
• Alternative excipients with better patient tolerability, such as plant-based or biodegradable options for oral or implantable formulations.

Existing patents limit immediate innovation, but off-patent formulations or biosimilars could prioritize excipient strategy optimization.

Summary

Eplerenone’s success relies partly on excipient choices that deliver stability, bioavailability, and patient adherence. Opportunities exist through formulation innovation, patent extensions, cost strategies, and regional product adaptations.

---

Key Takeaways

• Common excipients for eplerenone include binders, disintegrants, lubricants, and coating agents.
• Formulation strategies focus on stability, bioavailability, and patient compliance.
• Opportunities include developing novel formulations, optimizing cost, and expanding into emerging markets.
• Patent-term extensions often depend on innovative excipient combinations and delivery systems.
• Regulatory approval benefits from excipients with well-established safety profiles, simplifying market entry.

---

5 Frequently Asked Questions

1. What excipients are typically used in eplerenone formulations?
Microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hypromellose (for coatings), and sweeteners in liquid forms.

2. How does excipient selection impact eplerenone's bioavailability?
Excipients like disintegrants enhance tablet disintegration and dissolution, directly affecting absorption efficiency.

3. Are novel excipients viable for eplerenone formulations?
Yes, if they demonstrate improved stability, bioavailability, or patient tolerability, and gain regulatory approval.

4. Can formulation innovation extend the patent life of eplerenone?
Yes, new formulations with unique excipient combinations or delivery systems may qualify for patent protection.

5. What market opportunities exist through excipient strategy?
Developing controlled-release versions, liquid formulations, or formulations for specific populations can open new markets or extend existing ones.

---

Citations

1. Pfizer. (2018). Prescribing information: Eplerenone (Inspra).
2. U.S. Food and Drug Administration. (2003). Approval package for Eplerenone.
3. Shah, V., et al. (2012). Formulation strategies for improved bioavailability of eplerenone. Journal of Pharmaceutical Sciences, 101(9), 3678-3689.
4. European Medicines Agency. (2019). Eplerenone summary of product characteristics.
5. Kanchana, S., et al. (2021). Advances in controlled-release oral drug delivery systems. Asian Journal of Pharmaceutics, 15(4), 562-573.